Genitourinary Drugs Market to Reach USD 33.37 Billion by 2032, Supported by Rising Prostate Cancer Incidence and Hormonal Therapy Demand – SNS Insider

According to SNS Insider, the global Genitourinary Drugs Market was valued at USD 29.69 billion in 2024 and is expected to reach USD 33.37 billion by 2032, expanding at a compound annual growth rate (CAGR) of 1.49% over 2025–2032. Market growth is primarily driven by the increasing prevalence of prostate cancer, hormonal disorders, and interstitial cystitis, combined with strong investments in oncology research, therapeutic development, and government-led awareness programs.

The global incidence of genitourinary diseases is rising sharply due to aging populations, sedentary lifestyles, and environmental exposure. With advancements in drug discovery, personalized treatment pathways, and broader access to urological care, the genitourinary drugs market continues to evolve as a vital segment of the global pharmaceutical industry.

Get free Sample Report of Genitourinary Drugs Market: https://www.snsinsider.com/sample-request/6876

Genitourinary Drugs Market Overview

Genitourinary drugs play a critical role in the treatment of conditions affecting the urinary and reproductive systems, including prostate cancer, urinary incontinence, benign prostatic hyperplasia (BPH), and hormonal imbalances. The market has witnessed a shift toward precision-based therapies, biologics, and hormone-modulating agents aimed at improving treatment efficacy and minimizing side effects.

Government initiatives promoting early screening, subsidized treatment programs, and awareness campaigns are fueling adoption, while pharmaceutical companies continue to expand their genitourinary portfolios through mergers, acquisitions, and clinical advancements.

Major Players in the Genitourinary Drugs Market Include:

• Abbott Laboratories
• Pfizer Inc.
• Eli Lilly and Company
• Bristol-Myers Squibb Co.
• Novartis AG
• F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
• GlaxoSmithKline plc (GSK)
• AstraZeneca plc
• Merck & Co., Inc.
• Bayer AG
• Teva Pharmaceutical Industries Ltd.
• Allergan plc
• Ionis Pharmaceuticals, Inc.
• Antares Pharma, Inc.

Genitourinary Drugs Market Segment Insights

By Indication

In 2023, the prostate cancer segment held a 27% share of the global genitourinary drugs market. This leadership stems from the high global prevalence of prostate cancer and the extensive pipeline of therapeutic developments from both public and private entities. Growing awareness, government-funded screening initiatives, and early diagnosis programs are driving treatment demand.

As per the American Society of Clinical Oncology (ASCO), more than 1.4 million men were diagnosed with prostate cancer globally in 2020, and the American Cancer Society reported 288,300 new cases and 34,700 deaths in the U.S. alone in 2023. Rising incidence among aging male populations underscores the urgent need for innovative, efficient therapies.

The interstitial cystitis segment is expected to record the fastest CAGR during 2025–2032. Affecting up to 8 million women and 4 million men in the U.S., the condition currently relies on limited oral treatment options. Elmiron (pentosan polysulfate sodium) remains the only FDA-approved oral drug, and ongoing R&D efforts are exploring alternative agents to address unmet clinical needs.

By Product

The hormonal therapy segment captured 25% market share in 2024, owing to its integral role in treating both malignant and benign urological conditions. Hormone-modulating agents, including androgens, estrogens, and selective hormone regulators, are key in managing prostate cancer, BPH, and gynecological disorders. The National Institutes of Health (NIH) has reported a steep rise in BPH prevalence, particularly among men over 60, emphasizing the growing reliance on hormone-based therapies.

Disorders such as polycystic ovary syndrome (PCOS) and menopause-related hormonal imbalance are also fueling demand. According to the World Health Organization (WHO), PCOS affects 6–13% of women of reproductive age, with many cases undiagnosed. Rising obesity, sedentary lifestyles, and dietary changes further contribute to hormonal health challenges. Hormone replacement therapy (HRT) continues to gain traction for its proven effectiveness in improving patient outcomes and quality of life.

The gynecological drugs segment is projected to expand steadily over the forecast period, supported by government initiatives to enhance women’s reproductive health and broaden access to targeted therapies addressing conditions like endometriosis, menopause, and urinary tract infections.

Regional Analysis

North America Dominates, While Asia Pacific Records Fastest Growth in the Genitourinary Drugs Market

North America accounted for 36.9% of total revenue in 2023, driven by advanced healthcare infrastructure, high awareness, and accelerated regulatory approvals. The United States generated over USD 8.34 billion in revenue, with growing patient numbers and increasing adoption of newly approved genitourinary drugs. Between 2020 and 2024, the FDA approved 26 GU cancer drugs, representing 10.2% of all oncology approvals, signaling active clinical innovation across prostate, urothelial, and renal cancers.

The Asia Pacific region is expected to post the fastest CAGR during 2025–2032. Rising healthcare awareness, increased screening programs, and large patient pools across China, Japan, and India are strengthening the region’s market presence. Governments are launching national reproductive health programs, improving insurance coverage, and promoting clinical research collaboration with international pharmaceutical firms.

Europe also maintains a significant market share, led by Germany, France, and the United Kingdom, supported by strong health systems and increasing focus on elderly patient care. The U.K. NHS continues to provide wide access to prostate and urinary treatments, while Germany’s aging population and robust public health funding reinforce demand.

Across Latin America, the Middle East, and Africa (LAMEA), market growth is supported by improving healthcare infrastructure, government health initiatives, and private sector investments. Countries such as Brazil, Saudi Arabia, and the UAE are rapidly expanding access to urological medications under national healthcare vision plans.

Recent Developments in the Genitourinary Drugs Market

• In March 2023, Pfizer Inc. announced a definitive merger with Seagen Inc., an antibody-drug conjugate (ADC) leader, to enhance development of precision-targeted therapies for prostate and bladder cancers.
• GSK plc released promising phase III EAGLE-2 and EAGLE-3 trial results for gepotidacin, a first-in-class oral antibiotic for uncomplicated urinary tract infections (uUTIs) in adult and adolescent females.
• AstraZeneca advanced trials for next-generation androgen receptor inhibitors aimed at addressing hormone-resistant prostate cancers.
• Roche (Genentech) reported new data on checkpoint inhibitors for metastatic renal cell carcinoma, showing improved patient survival rates.
• Bayer AG expanded access to its oncology drug Nubeqa (darolutamide) across Europe, further strengthening its position in the prostate cancer treatment segment.

Buy the Genitourinary Drugs Market Report Now: https://www.snsinsider.com/checkout/6876

Statistical Insights

• Prostate cancer accounts for over 27% of the total genitourinary drugs market share globally.
• Hormonal therapy treatments cover approximately one-quarter of total genitourinary drug revenue.
• North America contributes over one-third of market revenue, supported by a strong regulatory and R&D ecosystem.
• The Asia Pacific market is projected to grow at the fastest CAGR, driven by increasing healthcare investments and screening programs.
• Between 2020 and 2024, 26 new genitourinary cancer drugs received FDA approval, underscoring accelerating innovation in the field.

Other Trending Reports

Peripheral Neuropathy Market

Precision Diagnostics Market

Magnetic Resonance Imaging (MRI) Market

Human Papillomavirus (HPV) Vaccine Market

About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Contact Us:

Rohan Jadhav - Principal Consultant

Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)

Email: info@snsinsider.com